In a bid to extend its cash runway, Atreca has suspended the clinical development of its solid tumor monoclonal antibody ATRC-101, slashing staff numbers by 40%. The company will focus on its preclinical antibody-drug conjugate (ADC) assets instead.
The San Carlos, CA biotech’s Phase Ib ATRC-101…
Click here to view original post
